Cash & Equivalents
Guardant Health Cash & Equivalents increased by 125.1% to $1.1B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.0%, from $803.85M to $1.1B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -10.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong liquidity and capacity for investment, while a decrease may indicate high cash burn or significant capital deployment.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and highly liquid i...
Peer comparison
Standard across all industries; peers in biotech typically maintain high levels to support long-term clinical development cycles.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $938.91M | $832.69M | $492.29M | $573.67M | $215.34M | $158.61M | $141.95M | $223.71M | $271.17M | $457.36M | $1.13B | $1.13B | $1.04B | $688.37M | $629.76M | $803.85M | $735.48M | $689.52M | $489.42M | $1.1B |
| QoQ Change | — | -11.3% | -40.9% | +16.5% | -62.5% | -26.3% | -10.5% | +57.6% | +21.2% | +68.7% | +147.9% | -0.4% | -8.3% | -33.5% | -8.5% | +27.6% | -8.5% | -6.2% | -29.0% | +125.1% |
| YoY Change | — | — | — | — | -77.1% | -81.0% | -71.2% | -61.0% | +25.9% | +188.4% | +698.7% | +404.8% | +281.8% | +50.5% | -44.5% | -28.8% | -29.0% | +0.2% | -22.3% | +37.0% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Guardant Health's cash & equivalents?
- Guardant Health (GH) reported cash & equivalents of $1.1B in Q1 2026.
- How has Guardant Health's cash & equivalents changed year-over-year?
- Guardant Health's cash & equivalents increased by 37.0% year-over-year, from $803.85M to $1.1B.
- What is the long-term trend for Guardant Health's cash & equivalents?
- Over 5 years (2020 to 2025), Guardant Health's cash & equivalents has grown at a -10.1% compound annual growth rate (CAGR), from $832.98M to $489.42M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets immediately available to the company.